Roche Trial Offers Hope to Patients with Rare Kidney Disease

Roche trial offers hope to patients with rare kidney disease

A study of Roche's Gazyva has raised the prospect of a first approved therapy for the rare kidney disorder primary membranous nephropathy.

Genentech Announces Positive Phase III Results for Gazyva in Primary Membranous Nephropathy, Marking a Significant Milestone in This Autoimmune Disease

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Feb 16, 2026-

Roche Reports Positive Phase III MAJESTY Results Showing Gazyva Potential in Primary Membranous Nephropathy

Open the article to view the coverage from EuropaWire.eu

Roche eyes Gazyva label expansion on positive Phase III kidney disease data

Roche's Gazyva could become the first drug to gain approval in membranous nephropathy, pending regulatory decisions from the FDA and EMA.The post Roche eyes Gazyva label expansion on positive Phase III kidney disease data appeared first on Clinical Trials Arena.

Roche Trial Win In Rare Kidney Disease And What It Means For Valuation

Roche Holding (SWX:ROG) reported that its Phase III MAJESTY study in primary membranous nephropathy met its primary endpoint with Gazyva/Gazyvaro. The result positions Gazyva/Gazyvaro as a potential first approved treatment for this rare kidney condition. The outcome may support future regulatory submissions and broaden the medicine's approved indications. For you as an investor, this sits at the heart of what Roche does: prescription medicines …

Kidney disease affecting 96,000 Americans gets potential first treatment

Up to 30% with primary membranous nephropathy face kidney failure; Genentech’s Gazyva achieved higher two-year remission vs tacrolimus in Phase III MAJESTY.